title: Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Beyazit
authors.forename: Salih
authors.initials: S
authors.lastname: Aksu
authors.forename: Murat
authors.initials: M
authors.lastname: Kekilli
authors.forename: Ibrahim C
authors.initials: IC
authors.lastname: Haznedaroglu
authors.forename: Sadettin
authors.initials: S
authors.lastname: Kilickap
authors.forename: Hakan
authors.initials: H
authors.lastname: Goker
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D001772:Blood Cell Count; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008206:Lymphatic Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D010996:Pleural Effusion / Q000139:chemically induced / Q000000981:diagnostic imaging; D011743:Pyrimidines / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate